好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Moyamoya Disease Associated with Autoimmune Hemolytic Anemia: A Case Report
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
1-007
To present a novel association of moyamoya disease with autoimmune hemolytic anemia (AIHA).
Moyamoya disease is a rare cerebrovascular disease involving progressive stenosis of arteries around the Circle of Willis, leading to formation of prominent collateral circulations. Although etiology of the disease remains unknown, moyamoya is suggested to have a genetic component and possible autoimmune element. Various hemolytic diseases have also been associated with moyamoya, however, no association has yet been reported with AIHA.

Case report and literature review.

The patient is a previously healthy African American male presenting with AIHA at age 14, managed with prednisone and rituximab. Two years after being diagnosed with AIHA, the patient had an ischemic stroke. Imaging demonstrated marked stenosis of bilateral internal carotid arteries and irregularities of Circle of Willis branches, and extensive collateral circulation formation, consistent with moyamoya disease.

The patient may be presenting with a genetic mutation predisposing him to moyamoya, with AIHA as an environmental trigger, but lack of significant family history weakens this hypothesis. Another suggested etiology is autoimmune, with presence of autoantibodies in AIHA. The association is weakened by lack of inflammatory or arteriosclerotic changes on pathological analysis of affected vessels in moyamoya in previous literature.

Association of moyamoya with hemoglobinopathies suggests that hypoxic anemia secondary to hemolytic processes leads to release of cellular mediators contributing to the pathophysiology. This is supported by literature indicating presence of smooth muscle hyperplasia contributing to vessel occlusion in moyamoya. This hypothesis may be most relevant in our case, as the patient’s presentation 2 years after diagnosis of AIHA is consistent with a chronic process.

Attention to early diagnosis and treatment of potential moyamoya disease in patients with AHIA may be warranted.
Authors/Disclosures
Shreya Agarwal
PRESENTER
No disclosure on file
Dasul Jin, MD (University Hospitals Cleveland Medical Center) No disclosure on file
Siddharth Gupta, MD No disclosure on file
Xue Ming, MD (Dept of Neurosciences) Dr. Ming has nothing to disclose.